QT Imaging Announces Shipping Forty Breast Acoustic CT(TM) Scanners in 2025 and Meeting Its Revenue Guidance
MWN-AI** Summary
QT Imaging Holdings, Inc. (OTCQB: QTIH), a medical device company specializing in innovative body imaging systems, has announced a significant advancement in its operations for 2025. The company confirmed the shipment of 40 Breast Acoustic CT™ scanners, a substantial increase from the 12 units shipped in 2024, marking a year-over-year revenue growth of over 285%. QT Imaging reported that it successfully met its revenue guidance of more than $18 million for 2025 and anticipates ending the year with a robust financial position, projecting at least $10 million in cash reserves, a dramatic rise from $1.2 million at the end of the previous year.
Dr. Raluca Dinu, CEO of QT Imaging, stated that 2025 was a pivotal year as the company transitioned from early commercialization to more scaled operations, reflecting increased market adoption of its technology. This growth trajectory is supported by strategic partnerships, notably with NXC Imaging, Inc., a Canon Medical Systems USA subsidiary, and Gulf Medical Co. in Saudi Arabia, where the company is set to ship 80 scanners in 2026, targeting $39 million in projected revenue.
QT Imaging's strong performance comes amid efforts to enhance profitability and reduce debt, as detailed in their recent filings with the U.S. Securities and Exchange Commission. The company has underscored the importance of its innovative Breast Acoustic CT technology in improving patient care through safer and more accessible imaging methods.
As QT Imaging forges ahead, it remains committed to navigating potential risks and uncertainties while delivering on growth expectations and fulfilling its mission of improving global health outcomes through advanced medical imaging solutions.
MWN-AI** Analysis
QT Imaging's recent announcement regarding the shipment of 40 Breast Acoustic CT(TM) scanners in 2025 and its ability to meet revenue guidance is a significant positive signal for investors. The company experienced a remarkable year-over-year revenue growth of more than 285%, with 2025 revenue projected at over $18 million, a substantial increase from the previous year. This exceptional performance reflects QT Imaging's transition from early commercialization to scaled execution, demonstrating solid operational discipline and growing market acceptance.
The company's strategic partnerships, particularly with NXC Imaging, a subsidiary of Canon Medical Systems USA, and Gulf Medical Co. in Saudi Arabia, are pivotal to its growth trajectory. These collaborations are expected to facilitate enhanced distribution channels and a scalable sales model, setting the stage for projected revenues of $39 million in 2026 from the shipment of 80 scanners. This aligns with its Amended Distribution Agreement, which underscores the company's commitment to meeting minimum order quantities, thereby solidifying its market position.
Financially, QT Imaging's plan to end 2025 with at least $10 million in cash reserves, compared to $1.2 million at the end of 2024, positions the company favorably for future investments and expansion. However, as with any forward-looking statements, potential investors should remain cautious about associated risks, including the ability to commercialize technology and fluctuations in market demand.
Investors should consider adding QT Imaging to their portfolios, given its robust growth metrics, strategic partnerships, and strong market potential in the medical imaging field. Nevertheless, close attention should be paid to ongoing developments and financial disclosures to gauge the company’s ability to sustain this momentum. Overall, QT Imaging presents a compelling investment opportunity in a sector poised for innovation and expansion.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Represents Year-Over-Year Revenue Growth of More than 285%
Sales Increase Driven by Shipment of Forty Scanners in 2025, up from Twelve in 2024
Expects to End Year in a Strong Financial Position to Support Continued Growth
QT Imaging Holdings, Inc. (OTCQB: QTIH) (“QT Imaging” or the “Company”), a medical device company engaged in research, development, and commercialization of innovative body imaging systems, today confirms that it finalized the shipment of 40 scanners and met its revenue guidance of more than $18 million in 2025.
“2025 was a transitional year for QT Imaging as we moved from early commercialization to scaled execution. We met our objectives and shipped scanners in line with our plan, demonstrating growing market adoption and operational discipline. We expect to exit 2025 in a significantly stronger financial position, with projected year end cash of at least $10 million, compared to $1.2 million at the end of 2024,” said Dr. Raluca Dinu, Chief Executive Officer. “I would like to thank our board of directors, our team, all our commercial partners, and investors for their continued support as we position the Company for sustained growth.”
2025-2026 Sales Outlook
The Company reiterates $39 million in revenue in 2026 (shipment of 80 scanners). This target is in accordance with the minimum order quantities to be shipped per its Amended Distribution Agreement with its strategic business and distribution partner, NXC Imaging, Inc., a wholly owned subsidiary of Canon Medical Systems USA, as well as its previously announced distribution agreement with Gulf Medical Co. in Saudi Arabia.
On December 23, 2025, the Company also furnished a Current Report on Form 8-K to the U.S. Securities and Exchange Commission, which includes copies of its unaudited pro forma condensed consolidated statement of operations and comprehensive loss as of and for the three months ended each of September 30, June 30, and March 31, 2025, and December 31, 2024. These financial statements are provided to present all information necessary to understand the Company’s enhanced profitability and meaningful debt reduction in 2025.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements contain words such as “will,” and “expect,” or the negative thereof or comparable terminology, and include (without limitation) statements regarding QT Imaging Breast Acoustic CT imaging technology, and product sales growth and projected revenues and cash position. Forward-looking statements involve certain risks and uncertainties, and actual results may differ materially from those discussed in any such statement. These risks include, but are not limited to: research results from the use of the QT Imaging Breast Acoustic CT Scanner, the ability of QT Imaging Holdings to sell and deploy the QT Imaging Breast Acoustic CT Scanner, the ability to extend product offerings into new areas or products, the ability to commercialize technology, governmental approvals, unexpected occurrences that deter the full documentation and “bring to market” plan for products, trends, and fluctuations in the industry, changes in demand and purchasing volume of customers, unpredictability of suppliers, the ability to attract and retain qualified personnel, and the ability to move product sales to production levels. Additional factors that could cause actual results to differ are discussed under the heading “Risk Factors” and in other sections of QT Imaging Holdings’ filings with the SEC, and in its other current and periodic reports filed or furnished from time to time with the SEC. All forward-looking statements in this press release are made as of the date hereof, based on information available to QT Imaging Holdings as of the date hereof, and QT Imaging Holdings assumes no obligation to update any forward-looking statement.
About QT Imaging
QT Imaging Holdings, Inc. is a public (OTCQB: QTIH) medical device company engaged in research, development, and commercialization of innovative body imaging systems using low frequency sound waves. QT Imaging Holdings, Inc. strives to improve global health outcomes. Its strategy is predicated upon the fact that medical imaging is critical to the detection, diagnosis, and treatment of disease and that it should be safe, affordable, accessible, and centered on the patient’s experience. For more information on QT Imaging Holdings, Inc., please visit the Company’s website at www.qtimaging.com .
Breast Acoustic CT TM is a trademark of an affiliate of QT Imaging Holdings, Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251224991067/en/
For investor and media inquiries, please contact:
Stephen Kilmer
Head of Investor Relations
Stephen.Kilmer@qtimaging.com
Direct: (646) 274-3580
Jay Jennings
Chief Financial Officer
Jay.Jennings@qtimaging.com
FAQ**
How does QT Imaging Holdings, Inc. (OTCQB: QTIH) plan to sustain its growth trajectory following the impressive year-over-year revenue growth of over 285% achieved in 2025?
Can QT Imaging (QTIH) elaborate on the impact of its strategic partnership with NXC Imaging, Inc. on its anticipated revenue growth and scanner shipments for 2026?
What specific measures does QT Imaging Holdings (QTIH) have in place to mitigate risks associated with the commercialization of its Breast Acoustic CT Scanner technology?
How does QT Imaging (QTIH) aim to enhance its market adoption and operational scale as it transitions from early commercialization to more significant execution in 2026?
**MWN-AI FAQ is based on asking OpenAI questions about QT Imaging Holdi (OTC: QTIH).
NASDAQ: QTIH
QTIH Trading
-3.39% G/L:
$5.70 Last:
887 Volume:
$6 Open:
